- AB Science annonce la délivrance d’un brevet européen pour le masitinib dans le traitement de la mastocytose sévère avec une protection jusqu’en 2036
- AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
- AB Science:
- AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
- AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
- AB Science : La Cour d’Appel de Paris confirme la mise hors de cause du Président Directeur Général d’AB Science, Alain Moussy, et diminue le montant de la sanction imposée à AB Science
- AB Science annonce un léger décalage de la publication de son rapport financier annuel 2023
- AB Science announces a slight delay in the publication of its 2023 annual financial report
- AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA
- AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
More ▼
Key statistics
On Monday, AB Science SA (AB:PAR) closed at 2.03, 30.97% above the 52 week low of 1.55 set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.00 |
---|---|
High | 2.09 |
Low | 1.99 |
Bid | 2.01 |
Offer | 2.05 |
Previous close | 1.99 |
Average volume | 75.56k |
---|---|
Shares outstanding | 52.07m |
Free float | 35.24m |
P/E (TTM) | -- |
Market cap | 103.62m EUR |
EPS (TTM) | -0.3561 EUR |
Data delayed at least 15 minutes, as of May 13 2024 16:35 BST.
More ▼